Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
Want insights into the biggest revenue-changing events?
Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
The Natural History of Community-Associated MRSA Infections and Decolonization Strategies
Completed
Washington University School of Medicine
N/A
2007-03-01
The purpose of this study is to determine the natural history of community-associated
Staphylococcus aureus infections in both adult and pediatric patients by monitoring the rate
of recurrent infections in those colonized with S. aureus.
In addition, this study will evaluate the efficiency of commonly prescribed decolonization
measures in patients presenting with S. aureus skin and soft tissue infections.
Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)
Completed
LEO Pharma
Phase 2
2008-02-01
An international, multi-centre, prospective three arm parallel-group, phase II proof of
concept study comparing the efficacy and safety of two dosage regimens (BID 7 days and TID 7
days) of TD1414 2% cream and one dosage regimen (BID 7 days) of Bactroban® (mupirocin) 2%
cream in adults and children down to 2 years of age with impetigo or SITL. Furthermore an
evaluation of the pharmacokinetics of TD1414 2% cream TID for 7 days will be performed. A
total of 664 patients will be enrolled in a stepwise manner according to age groups starting
with the oldest age group.
The purpose of this study is to determine whether measures to eliminate the Staph germ from
the skin of the index patient (with a special ointment and soap) are more effective when
performed by everyone in the household rather than the patient alone, and whether these
methods are effective in preventing future Staph infections. The investigators hypothesize
that there will be a greater number of households who are successful in eradicating the
staph germ from the index patient when all members of the household participate than
households where only the index patient is treated.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
